Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

Journal of the American Medical Association

Volumn 290, Issue 16, 2003, Pages 2149-2158

  Kris, Mark G ^a,b   Natale, Ronald B ^c   Herbst, Roy S ^d   Lynch Jr , Thomas J ^e   Prager, Diane ^f   Belani, Chandra P ^g   Schiller, Joan H ^h   Kelly, Karen ⁱ   Spiridonidis, Harris ^j   Sandler, Alan ^k   Albain, Kathy S ^l   Cella, David ^m   Wolf, Michael K ⁿ   Averbuch, Steven D ⁿ   Ochs, Judith J ⁿ   Kay, Andrea C ⁿ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h University of Wisconsin Health   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Hematology/Oncology Consultants Inc   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRY SKIN; ERYTHEMA; FEMALE; HEMOPTYSIS; HUMAN; LUNG CAVITATION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS SYNDROME; SKIN TOXICITY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RADIOGRAPHY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142055937     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.16.2149     Document Type: Article

References (51)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536-1543.
3. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000;6:747-753.
4. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19(18 suppl):32S-40S.
5. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749-5754.
6. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57:4838-4848.
7. Allen LF, Cerna C, Gomez L, Yochmowitz M, Medina L, Weitman S. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients. Clin Cancer Res. 2000;6:4543S.
8. AI Hazaa A, Birchall MA, Bowen ID. ZD1839 (Iressa™), an EGFR-TK1, and cisplatin have an additive effect on programmed cell death in human head and neck squamous carcinoma cells in vitro. Clin Cancer Res. 2000;6:4542S.
9. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063.
10. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. In press.
11. Brabender J, Danenberg KD, Metzger R, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7:1850-1855.
12. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factors receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379-2385.
13. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32A:2070-2074.
14. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515-522
15. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer. 1996;74:86-91.
16. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2001;20:110-124.
17. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240-2250.
18. Herbst RS, Maddox A-M, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
19. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-4302.
20. Kusaba H, Tamura T, Nakagawa K, et al. A phase I intermittent dose-escalation trial of ZD1839 (Iressa™) in Japanese patients with solid malignant tumors. Clin Cancer Res. 2000;6:4543S.
21. Kris MG, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (Iressa™), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 2000;29(suppl 1):72.
22. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
23. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-220.
24. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55:285-295.
25. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.
26. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
27. Bailey R, Kris M, Wolf M, et al. Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients (pts) receiving gefitinib ("Iressa," ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer (NSCLC): IDEAL 1 and 2. Proc Am Assoc Cancer Res. 2003;1362.
28. Fleiss J. Statistical Methods for Rates and Proportions. London, England: John Wiley & Sons; 1981.
29. Natale RB, Skarin A, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ("Iressa") in IDEAL 2. Proc Am Soc Clin Oncol. 2002;21:292a.
30. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer. 2003;39:55-61.
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
32. Fossella FV, DeVore R, Kerr RN, et al, the TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
33. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
34. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Presented at: American Society of Clinical Oncology Annual Meeting; May 12-15, 2001; San Francisco, Calif.
35. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
36. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease, part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321-340.
37. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271-4272.
38. Saltz L, Rubin M, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin Cancer Res. 2001;7(suppl):3766S.
39. Shah NT, Miller VA, Kris MG, et al. Bronchioloalveolar histology and smoking history predict response to gefitinib (Iressa) [abstract]. Proc Am Soc Clin Oncol. 2003;22:628.
40. O'Connell J, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604-1614.
41. Savage D, Antman K. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
42. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692-1703.
43. Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predicts clinical response to ST1571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol. 2002;21:2a.
44. Heinrich MC, Corless CL, Duensing A, et al. PDG-FRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
45. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. ST1571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002;20:325-334.
46. Stallings-Mann M, Wharen R, Thomas CY. Resistance of glioblastoma cells to an EGFR kinase inhibitor is associated with maintenance of signaling by phosphatidylinositol-3-kinase (P13K) and constitutive phosphorylation of the Gab1/Gab2 adapter proteins. Proc Am Soc Clin Oncol. 2002;21:19a.
47. Sirotnak F, Zakowski M, Miller V, Scher H, Kris M. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885-4892.
48. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178-1184.
49. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002;16:984-993.
50. Hainaut P, Pfeifer GP. Patterns of p53 G to T transversions in lung cancer reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22:367-374.
51. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.